The optimal program for someone on a GLP-1 medication combines both types of exercise but prioritizes resistance training
Patients with risk factors for pancreatitis, gallbladder disease, or significant diabetic retinopathy require particular attention during treatment
While the complete results of the study have not yet been published, an initial press release in 2024 indicated that tirzepatide reduced the relative risk for the composite endpoint (HF urgent visit or hospitalization, oral diuretic intensification, or cardiovascular death) by 38%
The most frequently reported GLP-1 RA-induced gastrointestinal AE was nausea (8,988, 42.23%), diarrhea (4,666, 21.93%), and vomiting (4,660, 21.90%) in FAERS